Top Story

ASCO: Biomarker assays demonstrate utility for early-stage invasive breast cancer

February 8, 2016

ASCO has issued a new clinical practice guideline that endorses the use of several biomarker assays to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer and known hormone receptor and HER-2 status.

However, the guidance states no biomarker test other than ER, PR and HER-2 should be used to make choices of specific drugs or treatment regimens.

FDA News

FDA grants breakthrough therapy designation to IMMU-132 for triple-negative breast cancer

February 8, 2016
The FDA granted breakthrough therapy designation to sacituzumab govitecan for the treatment of patients with triple-negative breast cancer who have failed at least two…
In the Journals

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

February 8, 2016
Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping” — to prevent…
Breaking News

Senate health committee considers seven biomedical innovation bills

February 8, 2016
The U.S. Senate Committee on Health, Education, Labor and Pensions will consider seven bipartisan bills on biomedical innovation tomorrow, Feb. 9, at the first of three…
In the Journals

PSA testing rates differ among urologists, PCPs

February 8, 2016
PSA testing rates have declined overall since the U.S. Preventive Services Task Force made a recommendation against the test, but these declines were greater among…
More News Headlines »

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Meeting News CoverageVideo

VIDEO: Lutathera 'an exciting new option for therapy' in midgut neuroendocrine tumors

January 29, 2016
More »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today